KR20240004451A - Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 - Google Patents

Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 Download PDF

Info

Publication number
KR20240004451A
KR20240004451A KR1020237037954A KR20237037954A KR20240004451A KR 20240004451 A KR20240004451 A KR 20240004451A KR 1020237037954 A KR1020237037954 A KR 1020237037954A KR 20237037954 A KR20237037954 A KR 20237037954A KR 20240004451 A KR20240004451 A KR 20240004451A
Authority
KR
South Korea
Prior art keywords
binding protein
subject
ilt7
weeks
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037954A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 리즈
가보 일레이
리 얀
조른 드라파
존 레치포드
에드워드 햄몬드
Original Assignee
비엘라 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비엘라 바이오, 인크. filed Critical 비엘라 바이오, 인크.
Publication of KR20240004451A publication Critical patent/KR20240004451A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020237037954A 2021-05-04 2022-05-04 Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 Pending KR20240004451A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US63/183,886 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US63/197,789 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US63/242,768 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US63/249,953 2021-09-29
US202263326424P 2022-04-01 2022-04-01
US63/326,424 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (1)

Publication Number Publication Date
KR20240004451A true KR20240004451A (ko) 2024-01-11

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037954A Pending KR20240004451A (ko) 2021-05-04 2022-05-04 Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법

Country Status (10)

Country Link
US (1) US20240287176A1 (enExample)
EP (1) EP4333877A1 (enExample)
JP (1) JP2024516698A (enExample)
KR (1) KR20240004451A (enExample)
AU (1) AU2022270101A1 (enExample)
BR (1) BR112023023036A2 (enExample)
CA (1) CA3217278A1 (enExample)
IL (1) IL308132A (enExample)
MX (1) MX2023013015A (enExample)
WO (1) WO2022235758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
WO2024026388A1 (en) * 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN120076802A (zh) * 2022-09-30 2025-05-30 艾伯维公司 治疗化脓性汗腺炎的方法
JP2025540348A (ja) * 2022-12-12 2025-12-11 ビエラ バイオ インコーポレイテッド 筋炎の処置及び予防のための、抗ｉｌｔ７結合剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1964852T1 (sl) * 2005-12-20 2013-09-30 Sbi Biotech Co. Ltd. Proti-ilt7 protitelo
WO2010065536A2 (en) * 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
CA3117102A1 (en) * 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Also Published As

Publication number Publication date
MX2023013015A (es) 2023-11-15
AU2022270101A1 (en) 2023-10-05
CA3217278A1 (en) 2022-11-10
US20240287176A1 (en) 2024-08-29
EP4333877A1 (en) 2024-03-13
BR112023023036A2 (pt) 2024-01-23
WO2022235758A1 (en) 2022-11-10
JP2024516698A (ja) 2024-04-16
IL308132A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
US20240287176A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP5905534B2 (ja) 多発性硬化症を治療する方法
US20220288199A1 (en) Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
US12605376B2 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
EP3891184A1 (en) Method of treating neutrophilic conditions
JP2026082835A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
WO2024126431A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
JP2022552199A (ja) （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することによる天疱瘡を処置する方法
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
WO2024152001A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
HK40113661A (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法
KR20250162587A (ko) 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드
HK40100361A (en) Methods of treating atopic dermatitis with anti il-13 antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250502

Comment text: Request for Examination of Application